FY2024 Earnings Estimate for Theratechnologies Inc. Issued By Cantor Fitzgerald (NASDAQ:THTX)

Theratechnologies Inc. (NASDAQ:THTX) – Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for Theratechnologies in a report issued on Thursday, April 11th. Cantor Fitzgerald analyst L. Chen now expects that the company will post earnings per share of $0.00 for the year, up from their prior estimate of ($0.06). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Theratechnologies’ current full-year earnings is ($0.03) per share.

Theratechnologies (NASDAQ:THTX) last posted its earnings results on Wednesday, February 21st. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.16. The business had revenue of $23.45 million for the quarter. During the same period last year, the business posted ($0.36) earnings per share.

Theratechnologies Stock Down 4.7 %

THTX stock opened at $1.42 on Monday. The business has a fifty day moving average of $1.48 and a two-hundred day moving average of $1.57. The stock has a market cap of $34.36 million, a price-to-earnings ratio of -2.33 and a beta of 1.34. Theratechnologies has a 52-week low of $0.88 and a 52-week high of $4.30.

Institutional Investors Weigh In On Theratechnologies

A number of institutional investors have recently modified their holdings of THTX. HighTower Advisors LLC acquired a new stake in shares of Theratechnologies in the first quarter valued at $34,000. Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the first quarter valued at $36,000. Worth Venture Partners LLC grew its stake in shares of Theratechnologies by 11.8% in the first quarter. Worth Venture Partners LLC now owns 755,863 shares of the company’s stock valued at $1,870,000 after buying an additional 79,900 shares in the last quarter. Range Financial Group LLC acquired a new stake in shares of Theratechnologies in the first quarter valued at $35,000. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Theratechnologies in the second quarter valued at $33,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.